Revolutionizing genomic medicine with advanced diagnostic products and services
Revolutionizing genomic medicine with advanced diagnostic products and services
Is your lab looking to quickly launch a new NGS test?
Begin issuing clinical reports under your lab’s branding for cancer predisposition and other high volume tests in a matter of weeks, not months or years. From assay design and validation studies to NGS data analysis, interpretation and clinical report sign off we can help. Find out how.
Want to solve more rare disease cases, in less time?
Variantyx Unity™ test for rare disease diagnosis is like an exome test, but better. Find out why.
Want to offer healthy patients comprehensive genomic screening?
Variantyx Wellness™ test screens for 1,000s of genetic risks in a single assay. Find out more.
Interested in a longer, healthier life with genomic testing?
Only Variantyx Wellness™ test uses whole genome sequencing (WGS) to comprehensively screen your DNA for predisposition to hereditary cancer and other diseases, carrier status and pharmacogenomic effects - all within a single assay. Find out why this matters.
News & Events
-
Expanded coverage of repeat expansion loci
January 09, 2019
With a growing number of different pathogenic repeat expansions linked to human disease, genetic testing for this unique class of mutations is an important component of the diagnostic process for many patients.
Today we’re excited to share that we’ve expanded the number of pathogenic repeat expansion loci covered in our Variantyx Unity™ test to a total of 24, including FMR1, AR, CNBP, DMPK and more!
Expanded coverage of repeat expansion loci
We’re excited to share that Variantyx UnityTM test now covers 24 loci!
-
Looking ahead to 2019!
Thanks to all who joined us at the many events we participated in throughout 2018.
We appreciated the opportunity to meet with so many like minded people who are passionate about their work and about doing great science. We're looking forward to an even more exciting 2019, and hope to see you at one of our future events.
First up is ACMG in Seattle, WA. Stay tuned for more details ...
Looking ahead to 2019!
Thanks to all who joined us at events throughout 2018.
-
Spotlight on epilepsy
December 12, 2018
Seizure disorders can be difficult to diagnose given similar clinical presentations, overlaps with a wide variety of disorders that present with seizures as a symptom and the challenge of detecting complex mutations.
Read this week's post where we highlight the wide range of variants involved in seizure disorders and phenotypes, all of which are detected by the Variantyx Unity™ test.
Spotlight on epilepsy
Read this week's post about detecting complex pathogenic variants in seizure-associated genes ...
-
A clinically validated whole genome pipeline for structural variant detection and analysis
On Demand Webinar
Many benefits are inherent in whole genome sequencing (WGS) technology, including unique opportunities for detection of structural variants. Yet such analyses have generally not made their way into clinical practice.
Listen in as we describe the clinically validated WGS pipeline that we have developed for highly specific and sensitive detection of structural variants. We will discuss the combined use of breakpoint analysis, read depth ...
A clinically validated whole genome pipeline for structural variant detection and analysis
On Demand Webinar
-
Comprehensive hereditary cancer screening: Know the sequencing technology being used
October 10, 2018
In keeping with the theme of supporting breast cancer awareness during the month of October, we're featuring our previous post on the importance of del/dup analysis when evaluating risk of hereditary cancer. When reviewing available hereditary cancer screening tests, we find that 24 of the most commonly screened genes have described, cancer-associated del/dup mutations two exons or less in size. This is significant for two reasons ...
Comprehensive hereditary cancer screening: Know the sequencing technology being used
Read our recent post which discusses why this is important ...
